Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?

Abstract

Adoptive immunotherapy using genetically targeted T-cells has recently begun to achieve impressive clinical impact in selected tumor types. Furthermore, long-term follow-up studies indicate thus far that integrating viral vectors do not elicit clinically evident genotoxicity in T-cells, unlike hematopoietic stem cells. The optimism engendered by this clinical experience provides a platform for consideration of the extended use of this technology in other disease types. One area of particular interest entails the harnessing of regulatory T-cells (Tregs) in order to down-regulate unwanted immune responses. Increasing evidence supports the efficacy of this approach in pre-clinical models of autoimmune disease and allograft rejection. Nonetheless, questions remain about optimal host cell, transgene cargo, phenotypic stability of engineered cells in vivo and potential for toxicity. Here, we review the evidence that genetically engineered Tregs can effectively dampen pathogenic immune responses and critically evaluate the prospects for clinical development of this approach.

• Authors: Hannah Jethwa, Antonella A Adami, John Maher
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 150 Issue 1 Pg. 51-63 (Jan 2014) ISSN: 1521-7035 [Electronic] United States
• PMID: 24333533 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2013 Elsevier Inc. All rights reserved.

Topics

• Animals
• Autoimmune Diseases (immunology)
• Humans
• Immunotherapy, Adoptive
• Risk Assessment
• T-Lymphocytes, Regulatory (immunology)